↓ Skip to main content

Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance)

Overview of attention for article published in Journal of Clinical Oncology, February 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#9 of 22,148)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
119 news outlets
blogs
1 blog
twitter
214 X users
facebook
12 Facebook pages
video
1 YouTube creator

Citations

dimensions_citation
52 Dimensions

Readers on

mendeley
176 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance)
Published in
Journal of Clinical Oncology, February 2018
DOI 10.1200/jco.2017.75.5413
Pubmed ID
Authors

Temidayo Fadelu, Sui Zhang, Donna Niedzwiecki, Xing Ye, Leonard B. Saltz, Robert J. Mayer, Rex B. Mowat, Renaud Whittom, Alexander Hantel, Al B. Benson, Daniel M. Atienza, Michael Messino, Hedy L. Kindler, Alan Venook, Shuji Ogino, Kimmie Ng, Kana Wu, Walter Willett, Edward Giovannucci, Jeffrey Meyerhardt, Ying Bao, Charles S. Fuchs

Abstract

Purpose Observational studies have reported increased colon cancer recurrence and mortality in patients with states of hyperinsulinemia, including type 2 diabetes, obesity, sedentary lifestyle, and high glycemic load diet. Nut intake has been associated with a lower risk of type 2 diabetes, metabolic syndrome, and insulin resistance. However, the effect of nut intake on colon cancer recurrence and survival is not known. Patients and Methods We conducted a prospective, observational study of 826 eligible patients with stage III colon cancer who reported dietary intake on food frequency questionnaires while enrolled onto a randomized adjuvant chemotherapy trial. Using Cox proportional hazards regression, we assessed associations of nut intake with cancer recurrence and mortality. Results After a median follow-up of 6.5 years, compared with patients who abstained from nuts, individuals who consumed two or more servings of nuts per week experienced an adjusted hazard ratio (HR) for disease-free survival of 0.58 (95% CI, 0.37 to 0.92; Ptrend= .03) and an HR for overall survival of 0.43 (95% CI, 0.25 to 0.74; Ptrend= .01). In subgroup analysis, the apparent benefit was confined to tree nut intake (HR for disease-free survival, 0.54; 95% CI, 0.34 to 0.85; Ptrend= .04; and HR for overall survival, 0.47; 95% CI, 0.27 to 0.82; Ptrend= .04). The association of total nut intake with improved outcomes was maintained across other known or suspected risk factors for cancer recurrence and mortality. Conclusion Diets with a higher consumption of nuts may be associated with a significantly reduced incidence of cancer recurrence and death in patients with stage III colon cancer.

X Demographics

X Demographics

The data shown below were collected from the profiles of 214 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 176 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 176 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 22 13%
Researcher 21 12%
Student > Bachelor 21 12%
Other 15 9%
Student > Ph. D. Student 13 7%
Other 34 19%
Unknown 50 28%
Readers by discipline Count As %
Medicine and Dentistry 54 31%
Nursing and Health Professions 27 15%
Agricultural and Biological Sciences 7 4%
Biochemistry, Genetics and Molecular Biology 6 3%
Unspecified 6 3%
Other 16 9%
Unknown 60 34%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1071. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 February 2024.
All research outputs
#14,558
of 25,571,620 outputs
Outputs from Journal of Clinical Oncology
#9
of 22,148 outputs
Outputs of similar age
#299
of 344,553 outputs
Outputs of similar age from Journal of Clinical Oncology
#2
of 273 outputs
Altmetric has tracked 25,571,620 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,148 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.1. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 344,553 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 273 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.